Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.34 mg/mL

NCT05689099 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05689099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.34 mg/mL
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
January 17, 2023
Completion date
May 30, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, healthy participants